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Abstract: Preterm birth (PTB), defined as parturition prior to 37 weeks of gestation, is the leading cause
of morbidity and mortality in the neonatal population. The incidence and severity of complications of
prematurity increase with decreasing gestational age and birthweight. The aim of this review study is
to select the most current evidence on the role of oxidative stress in the onset of preterm complication
prevention strategies and treatment options with pre-clinical and clinical trials. We also provide a
literature review of primary and secondary studies on the role of oxidative stress in preterm infants
and its eventual treatment in prematurity diseases. We conducted a systematic literature search of
the Medline (Pubmed), Scholar, and ClinicalTrials.gov databases, retroactively, over a 7-year period.
From an initial 777 articles identified, 25 articles were identified that met the inclusion and exclusion
criteria. Of these, there were 11 literature reviews: one prospective cohort study, one experimental
study, three case-control studies, three pre-clinical trials, and six clinical trials. Several biomarkers
were identified as particularly promising, such as the products of the peroxidation of polyunsaturated
fatty acids, those of the oxidation of phenylalanine, and the hydroxyl radicals that can attack the DNA
chain. Among the most promising drugs, there are those for the prevention of neurological damage,
such as melatonin, retinoid lactoferrin, and vitamin E. The microbiome also has an important role
in oxidative stress. In conclusion, the most recent studies show that a strong relationship between
oxidative stress and prematurity exists and that, unfortunately, there is still little therapeutic evidence
reported in the literature.
Keywords: oxidative stress; preterm; future prospects; review; antioxidant
1. Introduction
Preterm birth (PTB), defined as parturition prior to 37 weeks of gestation, is the leading cause of
morbidity and mortality in the neonatal population. The incidence and severity of complications of
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prematurity increase with decreasing gestational age and birthweight. Every year, about 15 million
babies are premature (more than one in ten of all babies born around the world). All newborns are
vulnerable, but preterm babies are acutely so. Many preterm babies require special care just to remain
alive. Newborn deaths—those in the first month of life—account for 40% of all deaths among children
less than 5 years old. Prematurity is the world’s single biggest cause of newborn death, and the second
leading cause of all child deaths, after pneumonia. Many of the preterm babies who survive face a
lifetime of disability [1]. Multiple prospective studies have reported that premature newborns have
higher risks of long-term neurodevelopmental disabilities, such as intellectual disability (ID), blindness,
neurosensorial hearing loss, and cerebral palsy (CP). There are several risk factors accounting for
prematurity, such as assisted reproductive technologies that increase the rate of multiple births (twins,
triplets, or quadruples) and advanced maternal age [2]. Teenage pregnancy could also be a risk factor
for prematurity, but the putative role of this factor is controversial and seems to have declined in the
last 10 years [2,3]. Other maternal causes potentially related to premature births are inflammatory,
hormonal, and neurochemical pathologies that could influence a mother’s ability to take appropriate
care of the baby once born [4].
Some complications (e.g., necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP),
bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH)) are uncommon in late preterm
infants. Most complications are related to the dysfunction of immature organ systems. In some cases,
complications resolve entirely; in others, residual organ dysfunction remains [5,6]. The most common
complications in extremely preterm infants are cardiac (patent ductus arteriosus (PDA)), neurological
(poor sucking and swallowing reflexes, apneic episodes, IVH, developmental or cognitive delays),
ocular (ROP, myopia and/or strabismus), gastrointestinal (feeding intolerance, with increased risk of
aspiration, NEC), renal (metabolic acidosis, growth failure), infective (sepsis, meningitis), respiratory
(respiratory distress syndrome, respiratory insufficiency of prematurity, chronic lung disease and
BPD), and metabolic (hypoglycemia, hyperbilirubinemia, and metabolic bone disease—osteopenia of
prematurity) [7–9]. These complications might have a single common denominator: oxidative stress [10].
Oxidative stress is a pathophysiological mechanism associated with spontaneous PTB, which reflects
an imbalance between the systemic manifestation of reactive oxygen species (ROS) and a biological
system’s ability to readily detoxify the reactive intermediates or to repair the resulting damage.
An increase in oxidative stress has been demonstrated in infants requiring an oxygen resuscitation
supplement in the delivery room [11].
Sies and Jones affirm how the increased formation of the different ROS leads to molecular damage,
denoted as “oxidative distress”. The signaling and damaging properties of ROS, in particular the most
prevalent and best-studied cellular oxidant H2O2 and the superoxide anion radical (O2−), represent
the basis for the concept of redox homeostasis, with its components of oxidative eustress and oxidative
distress. Redox signaling is universally integrated with the central homeostatic mechanisms at the
molecular, organellar, cellular, tissue, and organismic levels [12].
Disturbances in the normal redox state of cells can cause toxic effects through the production
of peroxides and free radicals that damage all components of the cell, including proteins, lipids,
and DNA. Oxidative stress from oxidative metabolism causes base damage and DNA strand breaks.
Base damage is mostly indirect and caused by ROS-generated O2− (superoxide radical), OH (hydroxyl
radical), and H2O2 (hydrogen peroxide). Indeed, the highly reactive hydroxyl radical reacts with the
heterocyclic DNA bases and the sugar moiety near. At diffusion-controlled rates, hydrated electron
and H atom also add to the heterocyclic bases. These reactions lead to adduct radicals, further reactions
of which yield numerous products [13]. Furthermore, some ROS act as cellular messengers in redox
signaling. Thus, oxidative stress can disrupt normal mechanisms of cellular signaling, and thereby
cause organ damage.
Currently, an antioxidant is defined as any substance able to eliminate ROS and their
derivatives [14]. In chemistry, “anti-oxidant” is simply conceived as “a compound that removes reactive
species, mainly those oxygen-derived” [15]. Their functions can be classified into distinct defense lines,
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according to their mechanisms of action: (a) preventative agents that suppress new radicals formation
(which includes enzymes, such as superoxide dismutase (SOD), catalase (CAT) and glutathione
peroxidase (GPX), proteins that bind metals, like ferritin and ceruloplasmin, and minerals such as
selenium (Se), copper (Cu), and zinc (Zn) [16,17]); (b) radical scavenging agents that inhibit chain
initiation and/or propagation, which includes glutathione, albumin, vitamins C and E, carotenoids,
and flavonoids; (c) repair and de novo enzymes that repair and reconstitute cell membranes,
which include lipases, proteases, DNA repair enzymes, transferases, and methionine–sulfoxide
reductases; and (d) adaptation agents that generate appropriate antioxidant enzymes and transfer
them to the essential site of action [14,18]. Another category of antioxidants is peroxiredoxins (Prxs),
a ubiquitous family of cysteine-dependent peroxidase enzymes that play dominant roles in regulating
peroxide levels within cells. In addition, Prxs might act as modulators of inflammation, protecting
against cell death and facilitating tissue repair after damage [19,20]. In addition, the potential for
intracellular free radical production is greatly reduced by the ability of mitochondrial cytochrome
oxidase to function catalytically in the electron transport chain without releasing ROS [8–21].
Thus, a possible correlation between oxidative stress and the development of complications in
premature babies led us to perform an analysis of the available literature. Here, we synthesize recent
findings on the role of oxidative stress in the onset of preterm complications, prevention strategies,
and treatment options.
2. Search Strategy
We aimed to select the most current evidence on the role of oxidative stress in the onset of preterm
complications, prevention strategies, and treatment options. We reviewed the literature (primary and
secondary studies) on the role of oxidative stress in preterm infants, as well as its prevention. We searched
the Medline (Pubmed), Scholar, and ClinicalTrials.gov databases retroactively over a 5-year search
period. The following search terms were used: oxidative stress, free radical, antioxidant, redox, and ROS
paired with preterm, preterm birth, preterm delivery, prematurity, premature birth, and premature
delivery, “free radicals preterm”, “anti-oxidant preterm”, “drugs preterm”, “neurodevelopment preterm”,
“pre-clinical trials preterm born”, “clinical trials preterm born”, “retinopathy of prematurity”, “necrotizing
enterocolitis preterm”, and “bronchopulmonary dysplasia preterm”. The inclusion criteria were as
follows: original research, written in English, and published after 2013. The exclusion criteria were as
follows: pregnancy failure, abortions, stillbirths, preimplantation embryos, PTB from specific infections
(e.g., malaria), maternal therapy, sepsis, the population of the clinical trial under study with less than
50 preterms, and pre-clinical trials where clinical trials do not yet exist. Twenty-five articles were selected
based on the search criteria. For the sake of a rational flow of thoughts, we decided to first analyze the
pre-clinical studies, then the clinical trials.
3. Results
From the 777 initially shortlisted articles, we excluded 439 articles because of their publication date
(published more than 7 years ago). Subsequently, we read the abstracts of the 338 remaining articles, and,
among them, 313 were not included in our final analysis (167 had no relevant information, six were not
in English, and 140 matched at least one of the exclusion criteria). Therefore, a total of 25 articles were
included in the study. Of these, 11 were literature reviews, one was a prospective cohort study, one was
an experimental study, three were case-control studies, three were pre-clinical trials, and six were clinical
trials (Figure 1 and Table 1). The articles selected show a relationship between oxidative stress and the
possible development of complications in the preterm. Furthermore, given the absence of evidence for the
treatment of oxidative stress in the preterm, we have selected three pre-clinical trials that evaluate the
use of certain molecules able to prevent the development of neurological, gastroenteric, and respiratory
complications (Table 2). In addition, six therapeutic clinical trials were included, reporting evidence of a
protective role against the development of oxidative stress and neuronal damage and/or NEC, as the other
trials did not comply with the selection criteria (Table 3).
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Table 1. Papers included in the analysis.
Type of Study Review Article Experimental Study Preclinical trial Clinical trial
2020 DOI: 10.1177/1099800419900231 [17]DOI: 10.1016/j.freeradbiomed.2019.02.032 [5]
ClinicalTrials.gov Identifier: NCT04235673 [22]
ClinicalTrials.gov Identifier: NCT04304807 [23]
2019
DOI: 10.1016/j.freeradbiomed.2019.02.019 [6]
DOI: 10.1016/j.resp.2019.05.006 [24]
DOI: 10.1016/j.freeradbiomed.2019.06.008 [7]
DOI: 10.1016/j.freeradbiomed.2019.04.029 [21]
DOI: 10.1093/biolre/ioz119 [25]
DOI: 10.1186/s12931-019-1063-5 [26]
DOI: 10.1186/s12974-019-1486-4. [27]
DOI: 10.1016/j.biopha.2018.11.023 [28]
2018
DOI: 10.3389/fped.2018.00369 [10]
DOI: 10.3390/antiox7120193 [29]
DOI: 10.1155/2018/7397659 [30]
DOI: 10.1177/1099800418791028 [16]
DOI: 10.1016/j.redox.2018.04.022 [31]
ClinicalTrials.gov Identifier: NCT03154723 [32]
2017 DOI: 10.1016/j.redox.2017.03.011 [33] DOI: 10.1016/j.mrgentox.2017.10.003 [34]
2016 DOI: 10.1093/molehr/gav074 [35]
2015 DOI: 10.1016/j.arcped.2015.05.019 [36] ClinicalTrials.gov Identifier: NCT01193270 [37]
2014 ClinicalTrials.gov Identifier: NCT02068807 [38]
2013 ClinicalTrials.gov Identifier: NCT01172236 [39]
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Table 2. Preclinical studies on Substances that prevent oxidative stress in preterm.
Substances under Study α1-Microglobulin Caffeine Ankaferd Blood Stopper®
Preclinical trials
The heme and A1M confers early protection of the
immature brain following preterm intraventricular
hemorrhage J Neuroinflammation
Antioxidative effects of caffeine in a hyperoxia-based rat
model of bronchopulmonary dysplasia
Therapeutic and preventative effects of ankaferd
blood stopper in an experimental necrotizing
enterocolitis model
Authors Olga Romantsik, et al. [27] Stefanie Endesfelder, et al. [26] Mehmet Buyuktiryaki, et al. [28]
Year of publication 2019 2019 2019
Cavy (animal) Rabbits pups Rats pups Rats pups
Molecule Protein Methylxanthine Protein
Mechanisms of action
-Heme binding
-Reductase activity
-Radical scavenging
-Binding to mitochondria
-Reduced oxidative DNA damage
-Protective interference with the oxidative stress response
-Antagonism of adenosine receptors
-Full blocking of hyperoxia-induced oxidative
-Significantly reduced apoptosis
-Reduction intestinal lesion
-Antioxidant, antinflammatory, and antiapoptotic
properties
Distribution
Periventricular cerebellar regions with high
plasticity (white matter, subventricular zone, corpus
callosum, corona radiata, thalamocortical projection)
Pulmonary Intestinal
Administration Intracerebroventricular Intravenous Intraperitoneal
Posology 25µL 10 mg/kg every 48 h beginning on the day of birth 2 mL/kg by diluting 2 mL with saline at a ratio of 1:3
Protective role neuroprotective against brain damage followingpreterm IVH BPD NEC
Radical scavenger α1-microglobulin (A1M); bronchopulmonary dysplasia (BPD); necrotizing enterocolitis (NEC).
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Table 3. Clinical studies on drugs that prevent oxidative stress in preterm.
Drugs Lactoferrin Lutein Vitamin E Vitamin A Studies of Melatonin
Clinical trials
Supplementation with Lactoferrin in
Preterm
Newborns (lactoprenew)
Evaluation of Antioxidant
Activity of Oral Lutein in
Preterm and Term Newborn
Vitamin E for Extremely
Preterm Infants
Effects of Early Vitamin A
Supplementation on the Risk
for Retinopathy of
Prematurity in Extremely
Preterm Infants
Oral Melatonin as
Neuroprotectant in Preterm
Infants
Effect of Melatonin on Feeding
Intolerance and Incidence of
Necrotizing Enterocolitis in
Preterm Infants
Date January 2013 February 2014 November 2015 September 2018 January 2020 March 2020
Study phase 4 2 1 Not Applicable Not Applicable 4
Population Birthweight ≤ 1500 grand/or gestationalage ≤ 32 weeks
Preterm born neonates with
gestational age <30 weeks
Preterm infants < 27 weeks’
gestation and < 1000 g birth
weight
Premature infants weighing
less than 1500 g
Neonates born before 29 +
6-week gestation Preterm infants < 37 week
Total Population 1300 100 93 262 60 90
Mechanisms of action
Binds iron with high affinity and its
structure is unusually resistant to
proteolytic degradation.
Antioxidant sequestering free ions of
Fe2+ and thus preventing lipid
peroxidation and subsequent milk
oxidation
Activity of inhibition of
peroxidation of membrane lipids
is peculiarly important for the
photoreceptors and neurons
Effective lipid
membrane antioxidant
Effective lipid
membrane antioxidant
Potent
antioxidant/-inflammatory effect
potent
antioxidant/-inflammatory effect
Posology 100 mg/day 0.28 mg of lutein in two doses:within 6 h
α-tocopheryl acetate 50 IU/kg.
1 dose 1500 IU/day for 28 day 3 mg/kg/day for 15 days
20 mg/day in two doses of 10 mg
each with a 1-h interval in
between
Administration Enteral Enteral Intragastrical Enteral Enteral Enteral
Protective role Neuroprotective NeuroprotectiveROP
Reduce the incidence of death or
development of neural
impairment
ROP Neuroprotectant for cerebralischemia NEC
Retinopathy of prematurity (ROP); necrotizing enterocolitis (NEC).
Pharmaceuticals 2020, 13, 145 7 of 19
 4 of 20 
development of oxidative stress and neuronal damage and/or NEC, as the other trials did not comply 
with the selection criteria (Table 3). 
 
Figure 1. Flow diagram of the literature selection and review process. 
 
Figure 1. Flow diagram of the literature selection and review process.
4. Discussion
Oxidative stress or, rather, the imbalance between the newborn’s oxidizing and antioxidant factors,
seems to play an important role in the onset of the main pathologies of the premature infant, such as BPD,
ROP, NEC, IVH, periventricular leukomalacia (PVL), and punctated white matter lesions (PWMLs).
Multiple studies have reported that oxidative stress is among the main causes of PWMLs, with which it
shares risk factors, such as hyperoxia, hypoxia, ischemia–reperfusion hemorrhage, and maternal/fetal
inflammation. Indeed, the microglial inflammatory response in the cerebral white matter can generate
free radicals; for this reason, the optimal concentration of oxygen for the resuscitation of preterm
infants is strictly monitored [10].
Other studies have shown a close association between oxidative stress and NEC. The first study,
which evaluates the global oxidizing/antioxidant status of infants with and without NEC, highlighted
how preterms with NEC had higher values of total oxidant status (TOS) and on the oxidative stress
index (OSI) than did controls [40,41]. The serum levels of antioxidant capacity (TAC) were measured
as described by Erel [42], using the bleaching of the characteristic color of a more stable 2,2′-azino-bis
(3-ethylbenz-thiazoline- 6-sulfonic acid) radical cation by antioxidants. Total oxidant status (TOS) was
measured as the oxidation of ferrous ion to ferric ion in the presence of various oxidative species in acidic
medium and the measurement of the ferric ion by xylenol orange, as described by Erel [43]. The TOS
to TAC ratio was defined as the OSI and used as an indicator of the degree of oxidative stress [44].
The second study showed how higher levels of oxidative markers in cord blood plasma were present in
preterm infants with NEC [30]. Lavu et al., studied changes in glycogen synthase kinase 3 beta (GSK3β)
activity and its regulation by p38 mitogen-actived protein kinase (p38MAPK) in effecting senescence
to further delineate the molecular mechanisms involved in senescence. These authors found that
OS-induced P-p38MAPK activation is associated with functional downregulation of GSK3β and arrest
of cell cycle progression and senescence of amnion cells. Lack of nuclear translocation of β-Cat and its
excretion via exosomes further supports the postulation that GSK3β downregulation by p38MAPK
might stop cell proliferation preceding cell senescence [25]. This study can be paired with the study by
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Dutta et al., who found mechanistic differences between PTB and PPROM by revealing differences
in fetal membrane redox status, oxidative stress-induced damage, distinct signaling pathways, and
senescence activation [35].
Forde et al., underlined how care in a neonatal intensive care unit (NICU) is crucial for preventing
the onset of oxidative stress in preterm infants, assessing the impact of kangaroo mother care (KMC;
in which a parent holds an infant skin-to-skin on their bare chest for extended periods of time), on
physiologic measures of stress (abdominal temperature, heart rate, oxygen saturation, perfusion
index, near-infrared spectrometry), oxidative stress, and energy conservation in preterm infants.
These authors detected significantly lower levels of urinary allantoin, a biochemical marker of oxidative
stress, in preterm infants treated with 1 h of KMC the day prior, compared to controls, who had been
treated with incubator care the previous day. This suggests that infants treated with KMC exhibit
lower inflammatory tone over time, lending support to the practice of early KMC intervention in the
NICU to ultimately reduce stress and promote the health and wellbeing of preterm infants [17].
In a study comparing DNA strand breaks as one of many consequences of DNA oxidation in
white blood cells, malondialdehyde (an oxidative stress marker), catalase, superoxide dismutase
activity, and total antioxidant capacity (markers of antioxidant defense) in the cord blood plasma of
a group of 25 preterms and 25 full-term births, Norishadkam highlighted the greater susceptibility
to damage to the DNA of preterms compared to babies born at term [34]. Cai et al., assessed the
effect of feeding practices on gut microbiome development and oxidative stress in preterm infants [5].
Preterm infants fed human milk with human milk fortifier or formula-only diets showed a significant
increase in F2-isoprostane levels (p < 0.05) relative to those fed a diet of human milk with formula.
The gut microbiome of the infants fed the human milk with a fortifier diet showed a lower abundance
of Veillonella (p < 0.05) compared to that of infants fed the human milk with formula diet. The gut
microbiome of the infants fed the formula-only diet showed the lowest microbial diversity and the
highest relative abundance of Terrisporobacter (p < 0.05) compared to the gut microbiomes of the other
infants. A low abundance of Veillonella might be associated with the increased oxidative stress of
infants who were fed breast milk with a fortifier. By contrast, a high abundance of Terrisporobacter
and Peptoclostridium and low bacterial diversity might be associated with increased oxidative stress in
infants who are fed formula [15].
These results show that feeding practices affect the bacterial diversity and composition of the gut
microbiome, which is associated with oxidative stress in the very low birth weight (VLBW) of preterm
infants [8,45]. As reported by Marseglia et al. [21], the 2018 Odzemir study shows how the serum
neutrophil-lymphocyte ratio (NLR) appears to have a predictive role in the development of OS-related
diseases, as in the case of BPD; the periods of hypoxia and reoxygenation are sensitive, use the
activation of neutrophils, and are responsible for the increase in oxidative metabolism, thus forming
species reactive to oxygen and nitrogen [ROS and reactive nitrogen species (RNS), respectively] [46].
If these toxic products are not inactivated, their high chemical reactivity leads to damage to a variety of
cellular macromolecules, including proteins, carbohydrates, lipids, and nucleic acid; this damage can
progress to the death of lung cells [21].
These macromolecules, as described by the National Institutes of Health, are categorized as
biomarkers and, as such, are being studied in the context of the evaluation of different biological
processes (Biomarkers Definitions Working Group, 2001).
Analytical methods available to study OS include those aimed at detecting a potential risk of
oxidative stress, such as non-protein bound iron (NPBI) with its capacity to generate OH through
Fenton reaction, and those aimed at detecting direct oxidative damage to lipids, proteins, and DNA
(Figure 1). In addition, stress response proteins, ROS-forming enzymes (e.g., xanthine oxidase (XO),
uncoupled nitric oxide synthases (NOS), and nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase (NOX)), and the activity of antioxidant enzymes (e.g., superoxide dismutase (SOD), catalase,
and glutathione peroxidase (GPX)) can be used as OS biomarkers. [47] To better understand the
mechanisms underlying oxidative stress, antioxidant defense, and redox signaling, it is essential to
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assess the protein thiol redox state. However, this state is seldom assessed immunologically because of
the inability to distinguish reduced and reversibly oxidized thiols by Western blotting [48–54].
A modern, underappreciated opportunity exists to use Click PEGylation to realize the
transformative power of simple, time and cost-efficient immunological techniques. Click PEGylation
harnesses selective, bio-orthogonal Click chemistry to separate reduced and reversibly oxidized
thiols by selectively ligating a low molecular weight polyethylene glycol moiety to the redox state of
interest [55].
The dangerous effects of FRs are due to their property lack of stability and ability to react with
polyunsaturated fatty acids of cell membranes, proteins, polysaccharides, and nucleic acids [56].
Therefore, clinically useful biomarkers should be measured in a reliable and reproducible way (it must
be reasonably stable and present in accessible tissue or fluid), but it should also satisfy at least one
requirement, such as showing the specificity of the disease, having prognostic power or correlating
with disease activity [57]. There are several molecules that could be used, in theory, as biomarkers, but,
to date, these are not used in clinical practice. The main commitments are described below.
4.1. Molecules that Suffer Damage from FR
4.1.1. Proteins
Several amino acid residues can undergo oxidative modifications, including the oxidation of
sulfur-containing amino acid residues, the hydroxylation of aromatic groups, the nitration of tyrosine
residues, the chlorination of aromatic groups, or the conversion of some amino acid residues to
carbonyl derivatives [29]. Proteins are one of the main targets of ROS and RNS damage. Various
amino acid residues can undergo oxidative changes, such as oxidation of sulfur-containing amino acid
residues, hydroxylation of aromatic groups, nitration of tyrosine residues, chlorination of aromatic
groups, or conversion of some carbonyl-derivative amino acid residues. In the neonatal period,
one of the biomarkers typically measured is the oxidation of phenylalanine (Phe). The oxidation
of Phe is due to the attack of the hydroxyl radical (OH), which converts Phe into ortho-tyrosine
(o-Tyr) or meta-tyrosine (m-Tyr). Moreover, other byproducts of tyrosine, such as 3-nitrotyrosine
(3NO2–Tyr) and 3-chlorothyrosine (3Cl–Tyr), are also useful as biomarkers of nitrosative stress and
inflammation, respectively [29]. In the presence of peroxynitrite (ONOO), p–Tyr can be converted into
3NO2–Tyr, a specific biomarker for protein nitration [58]. Protein nitration and RNS signaling play a
role in cellular functions, such as inflammatory responses and apoptosis [59]. In fact, in another study,
the quantification of the 3Cl–Tyr/p–Tyr ratio in human milk samples could be of potential interest for the
assessment of inflammation in different clinical scenarios [60]. Similarly, 3Cl–Tyr, formed by the attack
of hypochlorous acid on p–Tyr through the action of the enzyme myeloperoxidase (MPO), is considered
a useful inflammatory biomarker. The results of these determinations are expressed as ratios, such as the
o–Tyr/Phe, m-Tyr/Phe, 3NO2–Tyr/p–Tyr, and 3Cl–Tyr/p–Tyr ratios. These markers have been validated
and extensively applied in the clinical setting in various human biofluid matrices, such as amniotic
fluid, urine, plasma, cerebrospinal fluid, or human milk in the newborn period [16,24,29,31,36,61–64].
In urine, in a pre-clinical study conducted on pig pups, we found a significant increase in both urinary
o–tyrosine and 8-oxodG levels after 15 min of hyperoxia by resuscitation [62]. Prematurity is associated
with protracted oxidative stress, and human milk is partially protective, as there is a reduction in
biomarkers in the urine like o–Tyr/Phe [63]
4.1.2. Lipids
The lipid peroxidation process and the damage by its byproducts are among those most described in
the literature on free radical damage. This process can take place enzymatically, through the oxidation
of arachidonic acid by cyclooxygenase and lipoxygenase, with the formation of prostaglandins,
prostacycline, thromboxane, leukotrienes, and lipoxins. All polyunsaturated fatty acids (PUFAs),
as such, can undergo this enzymatic oxidation, leading to the formation of protectins, maresins [65],
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and dihydroxy-PUFAs (diHPUFAs). However, a relevant finding is that we did not identify evidence
of the presence of enzymatic oxidation of fatty acid-derived lipid peroxidation markers in preterm
infants. Neonatal markers of PUFA peroxidation include isoprostanes (IsoPs) [66,67], isofurans
(IsoFs), dihomo-isoprostanes (Dihomo-IsoPs), neuroprostanes (NeuroPs), and neurofurans (NeuroFs).
These are non-enzymatic products from the oxidation of amino acid-free radicals and other PUFAs,
and are chemically stable. These compounds have been detected electively in lipid-rich tissues,
such as brain tissue, which, being rich in polyunsaturated lipids, is highly sensitive to oxidative
stress [16–21,25,29,30,33–35,40,42–59,61,65–67].
Deshpande and Cai performed a double-blind, randomized controlled trial conducted in very
preterm neonates (between 23 and < 28 weeks’ gestation) [68]. This assessed 5 days of parenteral
nutrition with a lipid emulsion containing 80% olive oil and 20% soybean oil vs. a pure soybean oil
emulsion. The rationale for this study was that olive oil could favor-preterm neonates by reducing
oxidative injury, but the authors did not find significant differences. Plasma F2-isoprostane levels
were used as a marker of in vivo oxidative stress and lipid peroxidation, and are considered the
“gold-standard” biomarker for this parameter [69].
4.1.3. Nucleic Acids
In physiological conditions, DNA is constantly subject to oxidative damage, but DNA repair
mechanisms usually correct these alterations. However, oxidative damage to DNA can be complicated
by the oxidative alteration of DNA repair enzymes. The oxidation of DNA components by ROS is the
main source of damage to DNA, resulting in various modifications, including nucleotide oxidation,
filament breaks, base loss, and adduct formation. Hydroxyl radicals can attack the DNA chain
and the nitrogen bases of DNA nucleotides or deoxyribose. The main damage for OS to DNA is
generally produced by guanosine-based oxidation products, such as 7,8-hydroxy-2′-deoxyguanosine
(8-oxodG or 8-OHdG), which can be measured quantitatively in urine, plasma, and cerebrospinal fluid,
among others, by high-performance liquid or gas chromatography coupled with mass spectrometry
(UPLC–MS/MS) [29,33,58,59,61,65–67]. Sánchez-Illana et al., have described a method for the
simultaneous detection of a panel of oxidative stress-related biomarkers for the quantification of
damage to proteins and DNA in human breast milk samples. The results demonstrate the feasibility of
this method for the analysis of a panel of oxidative stress-related biomarkers (2dG, m-Tyr, 3Cl–Tyr),
reporting ranges found in human milk [60].
4.2. Therapeutical View from Experimental to Clinical Evidence
The choice of which therapeutic treatment as the principal goal for a reduction in the production
of free radicals in premature born is still controversial and challenging. In this setting, even if no
guidelines are provided, several pre-clinical and clinical trials allow us to identify some substances as
potential antioxidants in this population.
4.2.1. Pre-Clinical Trials
Among the pre-clinical studies currently available, the authors of the current manuscripts have
identified three main studies. The first, from Romantsik et al., tested the administration of 25 µL of
intracerebroventricular α1-microglobulin in rabbit pups. This acts through the binding of the heme
group and the reduction in the synthesis of free radicals by its reductase activity. α1-microglobulin is
distributed to periventricular cerebellar regions with high plasticity, having a neuroprotective effect
against brain damage as a result of IVH preterm [27].
The second pre-clinical study evaluated the antioxidant effect of caffeine related to the state of
hyperoxia present in a cohort of rat pups with bronchopulmonary dysplasia. Intravenous caffeine
(10 mg/kg) was administered every 48 h, immediately after birth, in order to avoid elevated doses of
caffeine outside the therapeutic range that might induce pro-inflammatory responses [70]. This resulted
in reduced oxidative damage to DNA, and antagonism of adenosine receptors, a protective action
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against the response to oxidative stress, and complete interruption of oxidative damage induced
by pulmonary hyperoxia. All of the abovementioned features have been found to be linked with a
protective role in the development of BPD [26]. Pre-clinical data coming from newborn cavies (rats)
has raised the hypothesis of a potential caffeine-related loss of weight. This assumption seems to be
underlined by some clinical studies [71–73]. However, this is of a temporary nature.
The third pre-clinical study aimed to investigate whether treatment with Ankaferd Blood Stopper®
(ABS) reduced the severity of NEC in rat pups in an experimental NEC model. ABS is a folkloric herbal
extract used as a hemostatic agent in traditional Turkish medicine [74]. ABS consists of a standardized
mixture of Thymus vulgaris, Alpinia officinarum, Vitis vinifera, Glycyrrhiza glabra, and Urtica dioicaplant
extracts [75]. ABS influences inflammatory and hemostatic processes via its effect on the endothelium,
blood cells, angiogenesis, cellular proliferation, vascular dynamics, and cellular mediators [74–76],
through its antioxidant, anti-inflammatory, antimicrobial, anti-apoptotic, and wound healing accelerant
properties. In this trial, ABS was administered intraperitoneally to the pups in the NEC group.
The drug administration protocol started on day 1 of the study at a dose of 2 mL/kg by diluting with
2 mL of saline at a ratio of 1:3. The intervention group resulted in a significantly reduced apoptosis
rate and a reduction in the intestinal lesions. Given the above, the antioxidant, anti-inflammatory,
and anti-apoptotic intestinal properties reduced the NEC in this specific context [28] [Table 2].
4.2.2. Clinical Trials
Here, we describe the relevant clinical studies, in order of publication. A clinical study conducted
by Buonocore at the University of Siena enlisted 1300 newborns with a birth weight of 1500 g or a
gestational age of 32 weeks. The investigated cohort was divided into two groups: the experimental
group received a daily dose of 100 mg of lactoferrin at standard therapy, while the control group received
only standard therapy. Therefore, the main objective was to evaluate the antioxidant effect and the
neuroprotective role of lactoferrin and its ability to reduce diseases of free radicals [39]. This is the first
study in the literature to address the role of lactoferrin in preterms. It is well established how lactoferrin
is an iron-binding glycoprotein with multiple biological functions (iron absorption, anti-inflammatory,
immunomodulatory, antioxidant, host defense mechanism, anti-carcinogenicity) [77,78]. A pre-clinical
trial showed great promise in the field of neonatology, and for the care of premature newborns, in this
model, lactoferrin could protect the preterm rat brain against cerebral hypoxia-ischemia injury [79].
A study still in experimental phase 2, conducted by the University of Siena in 2014, enrolled 100
preterm born neonates with gestational age < 30 weeks, reported that retinoic acid (lutein), a derivative
of vitamin A, is a neuroprotective factor. This analysis showed the reduction in the outcome ROP
through a dose of 0.28 mg of lutein administered enterally every 6 h, and within the first 36 h of
life. These results underline how the inhibition of peroxidation of membrane lipids is of paramount
importance for the photoreceptors and neurons [38,80]. Ramani et al., in 2017, suggested that a
combination of vitamin A plus retinoic acid might be neuroprotective in extremely preterm mice at
higher risk of neurological impairment due to excess oxidative stress [81].
According to a phase 1 study conducted by several US universities in 2015, vitamin E could
also be considered a protective element. The purpose of this analysis was to test both the safety and
efficacy of administration of one dose of vitamin E, via a tube into the stomach, to extremely preterm
infants (less than 27 weeks’ gestation and less than 1000 g weight at birth). This pivotal trial examined
whether a single dose of vitamin E would be absorbed into the infants’ bloodstreams, increasing serum
α-tocopherol levels in the target range of 1–3 mg/dl. This was found to be linked with a reduction in
the incidence of death or neurodevelopmental impairment [37].
Recently, a review summarized and analyzed the state of the art and relation between vitamin A
levels and diseases of premature infants. However, although sufficient evidence suggests that vitamin
A supplementation is beneficial in preterm infants, the evidence is still lacking for recommended
methods for supplementation and dosing of vitamin A. Therefore, in this clinical trial, vitamin A,
with its well-known antioxidant effect on lipid membranes, was administered orally at 1500 IU/day for
Pharmaceuticals 2020, 13, 145 12 of 19
28 days, and seemed to have a protective effect related to the development of the ROP in relation to the
control group, in a study of 254 premature infants weighing less than 1500 g [32].
Melatonin is a naturally occurring neuroendocrine molecule secreted in response to environmental
light–dark cycles. Melatonin influences numerous physiological functions, including growth and
development, reproduction, and the immune response [82].
Then, acting via specific cell membranes and nuclear receptors, melatonin achieves powerful
neuroprotective effect via antioxidant, anti-apoptotic, and anti-inflammatory processes [83,84] and by
promoting neuronal and glial development [85,86]. Additional indirect antioxidant effects of melatonin
include the up-regulation of antioxidant enzymes and, crucially, the preservation of mitochondrial
integrity [87,88].
The University of Pavia has carried out a clinical trial on Melatonin (ME), where researchers
investigated the protective role against cerebral ischemia through its powerful antioxidant/inflammatory
effects. This study aimed to highlight how ME can prevent brain damage due to premature childbirth.
ME was administered orally at a dose of 3 mg/kg/day for 15 days in infants born before gestation of
29 weeks. This was a prospective and randomized study, double-blind controlled, and with two parallel
arms. Furthermore, ME was proven to have a good safety profile with no known adverse effects [22].
4.3. Future Prospects
The extremely brief half-life of free radicals does not allow for direct measurement of their
concentration in clinical settings; therefore, thanks to studies such as those of Stefanovic et al. [7], various
analytical strategies have been developed to evaluate the state of oxidation, such as evaluation—both
at the extracellular (plasma, serum, urine, amniotic, cerebrospinal fluid) and intracellular (erythrocytes,
leukocytes) level—of the oxidoreductive quotient of molecules containing disulfide bridges (SS),
such as glutathione in a reduced or oxidized state (GSH or GSSG), or cysteine–cystine (Cys–H or
Cys–SS), or the activity of antioxidant enzymes such as SOD, CAT, or GPX. In addition, Stefanovic et
al., have developed a new method of evaluation of the redox stage of GSH based on surface-enhanced
Raman spectroscopy (SERS), which exploits a silver colloid that improves the GSH signal and allows
the accurate measurement of micro-volumes (20 mcl) of blood [7]. This method, associated with
the use of UPLC-MS/MS, allows the study of oxidative stress byproducts related to specific tissue
components, such as proteins, lipids, carbohydrates, or nucleic acids measured in various body
biofluids. Torres-Cuevas et al., have developed a UPLC-MS/MS for recording the profiles of the relative
contents of IsoP, IsoF, NeuroP, and NeuroF in a total of 536 urine samples during the first 4 weeks
of life in 184 premature infants who did not develop any pathology associated with oxidative stress
during the neonatal period [33]. A prospective study of 90 preterm infants in Ain Shams University
neonatal intensive care units enrolled infants suffering from food intolerance in the form of abdominal
distension, gastric residue, or bloody stool. The first cohort of 45 children was given 20 mg (ME),
divided into two daily doses of 10 mg each with a 1-h interval between them, in addition to traditional
antibiotic treatment. The second group of 45 children received only standard antibiotic treatment.
Both groups were then compared regarding the incidence of necrotizing enterocolitis and the level of
the tumor necrosis alpha factor 72 h after starting treatment as a marker of oxidative stress, having a
protective role against the NEC [23].
Evidence derived from the literature strongly supports that melatonin is neuroprotective
for acute hypoxic-ischemic perinatal brain injury, mediated via its antioxidant, anti-apoptotic,
and anti-inflammatory properties. Melatonin is safe in its administration both during pregnancy and
after delivery with respect to the newborn, and can reduce white matter brain injury under conditions
of chronic fetal hypoxia [89].
Currently, therapeutic strategies to decrease antioxidant cascade, in neonates, are poor and limited.
Future prospective studies should be dedicated to verifying the promise of single pharmacotherapy to
determine the optimal therapeutic time window for brain protection and, when possible, to decrease
the risk of brain damage [Table 3].
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The lung microbiome has an important role in the maturation of the immune system [90]; this might
act through the production of metabolites, such as tryptophan catabolites, which are agonist of the aryl
hydrocarbon receptor (AhR) that regulates the production of antioxidant enzymes [91,92].
Lactobacilli have the ability to metabolize tryptophan into AhR agonists, suggesting an important
modulatory role of these bacteria on the OS [93,94]. Moreover, a study in mice reported that the
injection of Lactobacilli into the lungs could improve alveolar development [95].
All of these findings indicate a potential role of the microbiome in reducing the OS correlated to
BPD. This can be explained by their capacity to reduce macrophage production of pro-inflammatory
cytokines, which are responsible for amplifying OS [96].
According to the current literature, the relevance of OS biomarkers in preterm is well established,
highlighting the importance of identifying high-risk preterm newborns and predicting their short-
and long-term outcomes. Overcoming the technical and economic difficulties that preclude the
use of OS biomarkers and the appropriate treatments in clinical practice is challenging, but would
lead to an improvement for an accurate evaluation of OS and, consequently, the quality of care of
neonatal patients.
5. Conclusions
The most recent studies show that the relationship between oxidative stress and prematurity is
receiving increasing attention from the scientific community. Several biomarkers emerged from our
research, such as the products of the peroxidation of polyunsaturated fatty acids (PUFAs), those of the
oxidation of phenylalanine, and the hydroxyl radicals that can attack the DNA chain. None of the
biomarkers studied and listed above are currently used. Among the most promising drugs, according to
our study, are those for the prevention of neurological damage, such as melatonin, retinoid lactoferrin,
and vitamin E (Figure 2). The microbiome has an important role in oxidative stress; in fact, the use of
lactobacilli might be protective against OS lesions in preterm infants [97]. The search for new biomarkers,
the improvement of care within the NICU, and the use of new machines and increasingly precise
techniques for the study of oxidative stress products and related pathologies are guiding us towards
increasingly targeted interventions (preventive, diagnostic, and therapeutic). Based on this evidence, it is
possible to hypothesize that in the coming years, the diagnostic strategies aimed at identifying the risk
of the onset of conditions related to oxidative stress will be further refined, and the guidelines for their
prevention and treatment will be updated, thereby reducing mortality and morbidity.
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